NASDAQ: XYLOXylo Technologies Ltd Stock
$1.64+0.04 (+2.5%)
Updated May 1, 2024
XYLO Price
$1.64
Fair Value Price
N/A
Market Cap
$3.08M
52 Week Low
$1.54
52 Week High
$7.17
P/E
-0.17x
P/B
0.13x
P/S
0.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$91.72M
Earnings
-$16.03M
Gross Margin
12.9%
Operating Margin
-17.55%
Profit Margin
-17.5%
Debt to Equity
1.33
Operating Cash Flow
-$6M
Beta
0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XYLO Overview
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XYLO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XYLO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XYLO is good value based on its book value relative to its share price (0.13x), compared to the US Medical Devices industry average (3.68x)
P/B vs Industry Valuation
XYLO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more XYLO due diligence checks available for Premium users.
Be the first to know about important XYLO news, forecast changes, insider trades & much more!
XYLO News
Valuation
XYLO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
30.19x
Market
37.67x
XYLO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.13x
Industry
3.68x
XYLO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XYLO's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
XYLO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XYLO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.9M
Liabilities
$31.5M
Debt to equity
1.33
XYLO's short-term assets ($31.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XYLO's short-term assets ($31.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XYLO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XYLO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
XYLO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XYLO vs Medical Device Stocks
Xylo Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.